Why Psychedelic Stocks are NOT Cannabis 2.0 (Huge MindMed Stock Opportunity)
In today’s episode, we will be discussing why Psychedelic Stocks, like MindMed (MMED / MMEDF) and Compass Pathways (CMPS) are not Cannabis 2.0, and why psychedelic stock prices will not follow the same path. For those who remember, Pot Stocks skyrocketed on the news of legalization, and then quickly tumbled back down to earth.
Some have dismissed companies like MindMed (MMED/MMEDF) and Compass Pathways (CMPS) as just the cannabis hype 2.0.
This, however, could not be further from the truth.
To be clear stocks like, MindMed Stock ( MMED : NEO market) and (MMEDF : OTC market), and Compass Pathways stock, ticker symbol CMPS are nothing like cannabis stocks.
To explain why, we are going to discuss an article entitled , “Why The Psychedelics Market is not Cannabis 2.0”, written by Jeff Siegel.
Psychedelic stocks are comparables to biotech companies these days. The prospect of promising research is pushing valuations upwards There are plenty of psychedelic stocks have experienced triple-digit returns in the last twelve months:
MindMed Stock MMED/MMEDF): 864%
Numinuss Wellness (NUMI): 555%
Revive Therapeutics (RVV): 166%
Compass Pathways (CMPS): 88%
The psychedelic industry is only just commencing. Other psychedelic stocks will soon penetrate the market and early investors can benefits from the shroom boom with 10X to 20X gains.
#psychedelicstocks #shroomstocks #mindmedstock
https://www.benzinga.com/markets/cannabis/21/01/19008810/why-the-psychedelics-market-is-not-cannabis-2-0
Remember to Like, Subscribe, and SMAH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
